Stealth Peptides Inc. Reports Results from Phase I Clinical Drug Interaction Studies with Bendavia
4/9/2012 9:32:51 AM
BOSTON--(BUSINESS WIRE)--Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative therapies for diseases with unmet medical needs, announced today the results from three Phase I clinical trials of Bendavia, a novel compound that targets the mitochondrion to treat mitochondrial dysfunction, including ischemia reperfusion and microvascular injury. The studies evaluated the potential for interactions between Bendavia and several drugs routinely administered to patients undergoing in–hospital interventional procedures. During the studies, volunteers received a single dose of Bendavia administered as an intravenous infusion followed by a standard dose of heparin, aspirin or clopidogrel. Results from these clinical trials indicate that Bendavia does not appear to affect the pharmacodynamics of these commonly used drugs. Safety data from these studies and preliminary results also demonstrate that Bendavia appears to be safe and well–tolerated at the doses evaluated, with no serious adverse events reported. Pharmacokinetic analysis from related clinical studies also showed highly predictable dose–proportional exposure of Bendavia among volunteers.
comments powered by